Key terms
About OMER
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OMER news
Apr 09
7:40am ET
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
Apr 03
2:01am ET
Omeros Corporation’s $50M Buyback Plan: A Double-Edged Sword for Stock Stability
Apr 02
6:27am ET
Omeros (OMER) Gets a Hold from Needham
Apr 01
4:04pm ET
Omeros sees Q1 EPS (63c)-(58c)
Apr 01
4:03pm ET
Omeros reports Q4 EPS (15c) vs (60c) last year
Apr 01
3:26pm ET
Omeros options imply 9.4% move in share price post-earnings
Apr 01
7:05am ET
Options Volatility and Implied Earnings Moves Today, April 01, 2024
Apr 01
7:00am ET
Options Volatility and Implied Earnings Moves This Week, April 01 – April 05, 2024
Mar 22
2:35pm ET
Omeros options imply 4.8% move in share price post-earnings
Mar 11
2:34pm ET
Omeros options imply 11.0% move in share price post-earnings
Feb 16
11:22am ET
Biotech Alert: Searches spiking for these stocks today
Feb 08
4:11am ET
Omeros Expands Royalty Deal with DRI for OMIDRIA Sales
Feb 01
9:17am ET
Omeros receives $115M royalty payment from DRI Healthcare Acquisitions
No recent press releases are available for OMER
OMER Financials
Key terms
Ad Feedback
OMER Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OMER Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range